1. V. G. Kukes and D. Berry (eds.), Therapeutic Drug Monitoring: A Tool of Personalized Medicine [in Russian], International Association of Clinical Pharmacologists and Pharmacists Press, Moscow (2013).
2. Guidance on Bioavailability and Bioequivalence Studies for Orally Administered Drug Products – General Considerations, US Food and Drug Administration [internet]; [cited Jul. 20, 2016]; http://www.fda.gov/ohrms/dockets/ac/03/briefing/3995B1_07_GFI-BioAvail-BioEquiv.pdf
3. Immediate Release Solid Oral Dosage Forms. Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation, US Food and Drug Administration [internet]; [cited Jul. 20, 2016]; http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm-070636.pdf
4. Draft Guidance on Warfarin Sodium, US Food and Drug Administration [internet]; [cited Jul. 20, 2016]; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201283.pdf
5. Draft Guidance on Dabigatran Etexilate Mesylate, US Food and Drug Administration [internet]; [cited Jul. 20, 2016]; http://www.fda.gov/downloads/Drugs/GuidanceCompliance-RegulatoryInformation/Guidances/UCM308030.pdf